MFSA Guidance 1 min read

Circular in Relation to the Right to be Forgotten for Clients with Medical History of Oncological Diseases and Relative Changes to the Conduct of Business Rulebook – Applicable with effect from 20 November 2026

RegCanary analysis of a MFSA publication

Representative image

Why it matters

RegCanary's analysis of what this means for regulated firms.

the MFSA has issued a circular introducing a 'right to be forgotten' for clients with a history of oncological disease, alongside consequential amendments to the Conduct of Business Rulebook applicable to credit institutions offering retail products and services, effective 20 November 2026. For compliance teams, this is a conduct-of-business and consumer-protection matter with a data-protection overlay: retail onboarding journeys, credit application forms, medical questionnaires and underwriting-style health questions will need to be reviewed so that applicants are no longer required to disclose historical oncological conditions beyond the permitted lookback window. The practical workstream is threefold.

First, policy and rulebook mapping — confirm which provisions of the Conduct of Business Rulebook have been amended and update internal lending, onboarding and product-governance policies accordingly. Second, documentation and data — revise application forms, scripts, staff guidance and privacy notices, and reassess retention and processing of special-category health data, including lawful basis and minimisation. Third, controls and training — brief frontline, credit-assessment and complaints staff, embed monitoring to evidence that prohibited questions are not being asked, and put in place a route to remediate customers previously declined or penalised on the basis of historic illness.

With the effective date falling only days after publication, firms should treat this as a near-term implementation task rather than a long-cycle change programme. Risks include rulebook breaches, discrimination and unfair-treatment exposures, and GDPR scrutiny of health-data handling; the upside is a more inclusive, streamlined retail proposition and reduced friction in mortgage, personal lending and protection cross-sell for a large, underserved customer segment.

Who this affects

Sectors and firm types identified in the analysis.

  • General Regulation

Source

MFSA

Original publication, 16 November 2026

Read the original publication (opens in a new tab) mfsa.mt

This is RegCanary's analysis, not the regulator's text. It summarises and interprets the publication above; it is not the MFSA's original wording, and it is not legal advice. Always rely on the original source.

Share

Weekly Briefing

Get the weekly briefing.

The regulatory changes that matter, with RegCanary analysis of what they mean for your firm. Delivered every Friday. Unsubscribe anytime.

Need this tailored to your firm's permissions? Book a demo